Please assess the completion status of the following clinical trial:

Trial Title: Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females, aged between 18 and 75.~* Outpatients scheduled for screening or surveillance colonoscopy~* Subjects must be identified as having the clinical requirement for second colonoscopy within 2weeks of the initial colonoscopy.~* Women of childbearing potential must use at least one reliable method of contraception, be surgically sterilised or be abstinent.~* For female subjects, a negative serum pregnancy test is required before Methylene Blue MMX® tablets are dispensed to the subject.~* Post menopausal patients need to have a period of greater than 1year since last menstrual period.~* Subjects must be able to comprehend the full nature and purpose of the study, including possible risks and side effects.~* Subjects must be able to co-operate with the investigator and to comply with the requirements of the entire study.~* Signed written informed consent prior to inclusion in the study.~Exclusion Criteria:~* No Pregnant or lactating women, or women undergoing fertility treatment.~* No previous medical history of, or suspected hypersensitivity to the Methylene Blue and/or this formulations ingredients.~* No previous medical history of, or suspected hypersensitivity to the PEG based bowel cleansing preparation and/or this formulations ingredients.~* No previous medical history of gastrointestinal obstruction or perforation, toxic megacolon, major colonic resection, severe diverticulitis, heart failure (Class III or IV), serious cardiovascular disease.~* No ALT, AST, GGT, Bilirubin, Creatinine or Urea greater than 2.5 x the upper limit for normal, based on local laboratory testing.~* No clinical alarm symptoms or history of anaemia (previously recorded haemoglobin of less than 10mg/dL) or frank blood in the stool within the last 30 days prior to enrolment.~* No known deficiency of glucose-6-phosphate dehydrogenase.~* No known deficiency of NADPH reductase.~* No treatment within 5 weeks prior to randomisation with Fluoxetine (Prozac).~* No concurrent treatment, or previous treatment within 2 weeks with any of the prohibited psychiatric medications that may interact with Methylene Blue as listed in the Prohibited Medications section; Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinepherine Reuptake Inhibitors (SNRI's), listed Tricyclic anti-depressants or Monoamine oxidase A inhibitors.~* No concurrent treatment with anticoagulants, or antiaggregants, inducing an INR \> 1.5.~* No current enrolment in any other clinical trial, or previous enrolment in a clinical trial within the last 30 days.~* No other medical condition that in the investigators opinion would make the administration of the study drug or procedures hazardous to the subject.~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: PLACEBO_COMPARATOR): Biopsy samples collected during standard white light colonoscopy.
- Group B (Type: ACTIVE_COMPARATOR): Subjects who have had samples collected during a Group A colonoscopy, who require a second colonoscopy within 2 weeks. Prior to this second colonoscopy the subjects take Methylene Blue MMX tablets. Biopsies collected are compared to their previous group A colonoscopy for histone gamma H2AX activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).